Journal article

Publication year: 2021

Pages: 56-62

Journal: Catheterization & Cardiovascular Interventions

Volume number: 97

Issue number: 1

ISSN: 1522-1946

eISSN: 1522-726X

Open access status: Hybrid

DOI Link: https://doi.org/10.1002/ccd.28843

Publisher: Wiley

Abstract: 

Objectives The aim of this study was to evaluate very long-term results after unrestricted everolimus-eluting bioresorbable scaffolds (BRS) implantation.

Background Previous randomized studies mainly included selected patients differing from those seen during daily routine and long-term data from all-comers registries are sparse.

Methods Consecutive patients undergoing BRS implantation were included in this observational, single center study. Clinical follow-up was conducted up to 5 years. Endpoint of interest was the composite of target lesion failure (TLF), including target-vessel myocardial infarction and target lesion revascularization and cardiac death. Furthermore, ARC-defined scaffold thrombosis (ScT) were assessed.

Results A total of 176 patients with a median age of 64 (55 - 72) years were analyzed, of which 59.6% presented an acute coronary syndrome. A total of 183 mainly complex lesions (55.8%) were treated. At 5 years, the rate for TLF was 21.6%. Definite or probable ScT rate was 4.1%. The rate of ScT within the first year was 2.8% and afterwards 1.2%. Notably, no ScT was seen later than 2 years.

Conclusions Although this real-world registry displays high rates of clinical events during long-term follow-up, no ScT was seen after 2 years.

Harvard Citation style: Wiebe, J., Hofmann, F., Doerr, O., Bauer, T., Boeder, N., Liebetrau, C., et al. (2021) Five-year follow-up of patients who underwent everolimus-eluting bioresorbable scaffold implantation, Catheterization & Cardiovascular Interventions, 97(1), pp. 56-62. https://doi.org/10.1002/ccd.28843

APA Citation style: Wiebe, J., Hofmann, F., Doerr, O., Bauer, T., Boeder, N., Liebetrau, C., Blachutzik, F., Moellmann, H., Elsaesser, A., Achenbach, S., Hamm, C., & Nef, H. (2021). Five-year follow-up of patients who underwent everolimus-eluting bioresorbable scaffold implantation. Catheterization & Cardiovascular Interventions. 97(1), 56-62. https://doi.org/10.1002/ccd.28843